127 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Board
8-K
EX-99.1
wlhqd1
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
424B5
urfcz 1cvlcmlcdwk
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
j8l62f
24 Jul 23
Regulation FD Disclosure
4:04pm
424B5
rbbhd f3ssju
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.2
x0q h82x65fhkm8vmlbu
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
cv626 502
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
wo0ky 3ph
10 May 23
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
5:17pm
8-K
EX-99.1
zn52giu1xtlj
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-99.1
ztv6aj0e4 v4nsch
17 Oct 22
Regulation FD Disclosure
5:13pm